NXTC

SEC source: 0001213900-26-088156 · ownership.xml · nonDerivative · entry 1

Simcere Zaiming, Inc. · CIK 0002080252 · Former 10% Owner

Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. · CIK 0002082506 · Former 10% Owner

Simcere Zaiming Pharmaceutical Co., Ltd. · CIK 0002088064 · Former 10% Owner

Simcere Pharmaceutical Group Ltd · CIK 0002082516 · Former 10% Owner

Ren Jinsheng · CIK 0001455397 · Former 10% Owner

Tang Renhong · CIK 0002088593 · Former 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 308,636

F1 · ownership.nature: The securities reported herein were directly held by Simcere Zaiming, Inc. ("Simcere Zaiming") and may be deemed to have been indirectly beneficially owned by the other Reporting Persons.

F2 · ownership.nature: Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. ("Jiangsu Zaiming") is the sole shareholder of Simcere Zaiming. Simcere Zaiming Pharmaceutical Co., Ltd. (formerly known as Hainan Simcere Zaiming Pharmaceutical Co., Ltd.) is the sole shareholder of Jiangsu Zaiming. Simcere Pharmaceutical Group Limited ("Simcere Group") is the controlling shareholder of Simcere Zaiming Pharmaceutical Co., Ltd. through several intermediate companies. Mr. Jinsheng Ren is the chairman of the board of directors of Simcere Group and a director of Simcere Zaiming Pharmaceutical Co., Ltd. Mr. Renhong Tang is a director of Simcere Group, the chief executive officer and chairman of the board of directors of Simcere Zaiming Pharmaceutical Co., Ltd., a director of Jiangsu Zaiming and the chief executive officer and sole director of Simcere Zaiming. Messrs. Ren and Tang may be deemed to be the beneficial owners having shared voting power and shared investment power over the securities described herein.

F3 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that any Reporting Person is the beneficial owner of any of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.

SEC source: 0001940272-26-000013 · primary_doc.xml · nonDerivative · entry 9

ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner

Schneeberger Daniel · CIK 0001861120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 722,419

F6 · ownership.nature: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.

F7 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001940272-26-000013 · primary_doc.xml · nonDerivative · entry 8

ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner

Schneeberger Daniel · CIK 0001861120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 714,416

F5 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9740 to $4.9824, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F6 · ownership.nature: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.

F7 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001940272-26-000013 · primary_doc.xml · nonDerivative · entry 7

ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner

Schneeberger Daniel · CIK 0001861120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 689,416

F4 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9100 to $5.0000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F6 · ownership.nature: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.

F7 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001940272-26-000013 · primary_doc.xml · nonDerivative · entry 6

ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner

Schneeberger Daniel · CIK 0001861120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 686,116

F3 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.7563 to $5.0000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F6 · ownership.nature: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.

F7 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001940272-26-000013 · primary_doc.xml · nonDerivative · entry 5

ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner

Schneeberger Daniel · CIK 0001861120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 608,266

F6 · ownership.nature: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.

F7 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001940272-26-000013 · primary_doc.xml · nonDerivative · entry 4

ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner

Schneeberger Daniel · CIK 0001861120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 508,266

F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.8100 to $4.8450, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F6 · ownership.nature: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.

F7 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001940272-26-000013 · primary_doc.xml · nonDerivative · entry 3

ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner

Schneeberger Daniel · CIK 0001861120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 483,266

F6 · ownership.nature: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.

F7 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001940272-26-000013 · primary_doc.xml · nonDerivative · entry 2

ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner

Schneeberger Daniel · CIK 0001861120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 463,266

F6 · ownership.nature: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.

F7 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001940272-26-000013 · primary_doc.xml · nonDerivative · entry 1

ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner

Schneeberger Daniel · CIK 0001861120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 443,266

F1 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9000 to $5.0000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F6 · ownership.nature: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.

F7 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001940272-26-000012 · primary_doc.xml · nonDerivative · entry 4

ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner

Schneeberger Daniel · CIK 0001861120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 393,266

F2 · ownership.nature: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.

F3 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001940272-26-000012 · primary_doc.xml · nonDerivative · entry 3

ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner

Schneeberger Daniel · CIK 0001861120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 391,666

F2 · ownership.nature: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.

F3 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001940272-26-000012 · primary_doc.xml · nonDerivative · entry 2

ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner

Schneeberger Daniel · CIK 0001861120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 389,856

F1 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9000 to $5.0000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F2 · ownership.nature: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.

F3 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001940272-26-000012 · primary_doc.xml · nonDerivative · entry 1

ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner

Schneeberger Daniel · CIK 0001861120 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 383,456

F2 · ownership.nature: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.

F3 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0000905148-26-003044 · form4.xml · derivative · entry 1

KABAKOFF DAVID S · CIK 0001024008 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,510

Underlying: Common Stock · 3,510 shares

Expires 2036-06-17

F1 · derivative.exercise_date: The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.

SEC source: 0000905148-26-003048 · form4.xml · derivative · entry 1

Borgman Anne Elizabeth · CIK 0001886388 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,340

Underlying: Common Stock · 2,340 shares

Expires 2036-06-17

F1 · derivative.exercise_date: The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.

SEC source: 0000905148-26-003043 · form4.xml · derivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,340

Underlying: Common Stock · 2,340 shares

Expires 2036-06-17

F1 · derivative.exercise_date: The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.

SEC source: 0000905148-26-003045 · form4.xml · derivative · entry 1

Jones Elaine V · CIK 0001296907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,340

Underlying: Common Stock · 2,340 shares

Expires 2036-06-17

F1 · derivative.exercise_date: The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.

SEC source: 0000905148-26-003047 · form4.xml · derivative · entry 1

Feigal Ellen · CIK 0001758108 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,340

Underlying: Common Stock · 2,340 shares

Expires 2036-06-17

F1 · derivative.exercise_date: The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.

SEC source: 0000905148-26-003046 · form4.xml · derivative · entry 1

Houston John G · CIK 0001753537 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,340

Underlying: Common Stock · 2,340 shares

Expires 2036-06-17

F1 · derivative.exercise_date: The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.

SEC source: 0000905148-26-000477 · form4.xml · derivative · entry 1

Guha Udayan · CIK 0002054923 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,670

Underlying: Common Stock · 14,670 shares

Expires 2036-01-29

F1 · derivative.exercise_date: One fourth of the option vests on January 30, 2027. The remainder vests in 36 monthly installments beginning on February 28, 2027.

SEC source: 0000905148-26-000478 · form4.xml · derivative · entry 1

Mayer Timothy · CIK 0001775460 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,670

Underlying: Common Stock · 14,670 shares

Expires 2036-01-29

F1 · derivative.exercise_date: One fourth of the option vests on January 30, 2027. The remainder vests in 36 monthly installments beginning on February 28, 2027.

SEC source: 0000905148-26-000480 · form4.xml · derivative · entry 1

Richman Michael · CIK 0001366265 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,190

Underlying: Common Stock · 38,190 shares

Expires 2036-01-29

F1 · derivative.exercise_date: One fourth of the option vests on January 30, 2027. The remainder vests in 36 monthly installments beginning on February 28, 2027.

SEC source: 0000905148-26-000481 · form4.xml · derivative · entry 1

Shaw Kevin G. · CIK 0001953666 · Sr VP, General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,270

Underlying: Common Stock · 8,270 shares

Expires 2036-01-29

F1 · derivative.exercise_date: One fourth of the option vests on January 30, 2027. The remainder vests in 36 monthly installments beginning on February 28, 2027.

SEC source: 0000905148-26-000479 · form4.xml · derivative · entry 1

Kundu Sourav · CIK 0001872985 · Sr VP, Dev. & Mfg.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,270

Underlying: Common Stock · 8,270 shares

Expires 2036-01-29

F1 · derivative.exercise_date: One fourth of the option vests on January 30, 2027. The remainder vests in 36 monthly installments beginning on February 28, 2027.

SEC source: 0000905148-26-000476 · form4.xml · derivative · entry 1

Cobourn Steven P. · CIK 0001775457 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,670

Underlying: Common Stock · 14,670 shares

Expires 2036-01-29

F1 · derivative.exercise_date: One fourth of the option vests on January 30, 2027. The remainder vests in 36 monthly installments beginning on February 28, 2027.

SEC source: 0000905148-25-002244 · form4.xml · derivative · entry 1

KABAKOFF DAVID S · CIK 0001024008 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,050

Underlying: Common Stock · 28,050 shares

Expires 2035-06-19

F1 · derivative.exercise_date: The option vests in full on the earlier of June 20, 2026 and the date of the 2026 Annual Meeting of Stockholders.

SEC source: 0000905148-25-002243 · form4.xml · derivative · entry 1

Borgman Anne Elizabeth · CIK 0001886388 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,700

Underlying: Common Stock · 18,700 shares

Expires 2035-06-19

F1 · derivative.exercise_date: The option vests in full on the earlier of June 20, 2026 and the date of the 2026 Annual Meeting of Stockholders.

SEC source: 0000905148-25-002242 · form4.xml · derivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,700

Underlying: Common Stock · 18,700 shares

Expires 2035-06-19

F1 · derivative.exercise_date: The option vests in full on the earlier of June 20, 2026 and the date of the 2026 Annual Meeting of Stockholders.

SEC source: 0000905148-25-002245 · form4.xml · derivative · entry 1

Jones Elaine V · CIK 0001296907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,700

Underlying: Common Stock · 18,700 shares

Expires 2035-06-19

F1 · derivative.exercise_date: The option vests in full on the earlier of June 20, 2026 and the date of the 2026 Annual Meeting of Stockholders.

SEC source: 0000905148-25-002246 · form4.xml · derivative · entry 1

Houston John G · CIK 0001753537 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,700

Underlying: Common Stock · 18,700 shares

Expires 2035-06-19

F1 · derivative.exercise_date: The option vests in full on the earlier of June 20, 2026 and the date of the 2026 Annual Meeting of Stockholders.

SEC source: 0000905148-25-002241 · form4.xml · derivative · entry 1

Feigal Ellen · CIK 0001758108 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,700

Underlying: Common Stock · 18,700 shares

Expires 2035-06-19

F1 · derivative.exercise_date: The option vests in full on the earlier of June 20, 2026 and the date of the 2026 Annual Meeting of Stockholders.

SEC source: 0000905148-25-000336 · form4.xml · derivative · entry 1

Mayer Timothy · CIK 0001775460 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,375

Underlying: Common Stock · 117,375 shares

Expires 2035-01-30

F1 · derivative.exercise_date: One fourth of the option vests on January 31, 2026. The remainder vests in 36 monthly installments beginning on February 28, 2026.

SEC source: 0000905148-25-000332 · form4.xml · derivative · entry 1

Richman Michael · CIK 0001366265 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 305,500

Underlying: Common Stock · 305,500 shares

Expires 2035-01-30

F1 · derivative.exercise_date: One fourth of the option vests on January 31, 2026. The remainder vests in 36 monthly installments beginning on February 28, 2026.

SEC source: 0000905148-25-000337 · form4.xml · derivative · entry 1

Shaw Kevin G. · CIK 0001953666 · Sr VP, General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,125

Underlying: Common Stock · 66,125 shares

Expires 2035-01-30

F1 · derivative.exercise_date: One fourth of the option vests on January 31, 2026. The remainder vests in 36 monthly installments beginning on February 28, 2026.

SEC source: 0000905148-25-000335 · form4.xml · derivative · entry 1

Langermann Sol · CIK 0001775459 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,375

Underlying: Common Stock · 117,375 shares

Expires 2035-01-30

F1 · derivative.exercise_date: One fourth of the option vests on January 31, 2026. The remainder vests in 36 monthly installments beginning on February 28, 2026.

SEC source: 0000905148-25-000334 · form4.xml · derivative · entry 1

Kundu Sourav · CIK 0001872985 · Sr VP, Dev. & Mfg.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,125

Underlying: Common Stock · 66,125 shares

Expires 2035-01-30

F1 · derivative.exercise_date: One fourth of the option vests on January 31, 2026. The remainder vests in 36 monthly installments beginning on February 28, 2026.

SEC source: 0000905148-25-000333 · form4.xml · derivative · entry 1

Cobourn Steven P. · CIK 0001775457 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,375

Underlying: Common Stock · 117,375 shares

Expires 2035-01-30

F1 · derivative.exercise_date: One fourth of the option vests on January 31, 2026. The remainder vests in 36 monthly installments beginning on February 28, 2026.

SEC source: 0000905148-24-001768 · form4.xml · derivative · entry 1

KABAKOFF DAVID S · CIK 0001024008 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,050

Underlying: Common Stock · 28,050 shares

Expires 2034-06-19

F1 · derivative.exercise_date: The option vests in full on the earlier of June 20, 2025 and the date of the 2025 Annual Meeting of Stockholders.

SEC source: 0000905148-24-001764 · form4.xml · derivative · entry 1

Borgman Anne Elizabeth · CIK 0001886388 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,700

Underlying: Common Stock · 18,700 shares

Expires 2034-06-19

F1 · derivative.exercise_date: The option vests in full on the earlier of June 20, 2025 and the date of the 2025 Annual Meeting of Stockholders.

SEC source: 0000905148-24-001769 · form4.xml · derivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,700

Underlying: Common Stock · 18,700 shares

Expires 2034-06-19

F1 · derivative.exercise_date: The option vests in full on the earlier of June 20, 2025 and the date of the 2025 Annual Meeting of Stockholders.

SEC source: 0000905148-24-001767 · form4.xml · derivative · entry 1

Jones Elaine V · CIK 0001296907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,700

Underlying: Common Stock · 18,700 shares

Expires 2034-06-19

F1 · derivative.exercise_date: The option vests in full on the earlier of June 20, 2025 and the date of the 2025 Annual Meeting of Stockholders.

SEC source: 0000905148-24-001766 · form4.xml · derivative · entry 1

Houston John G · CIK 0001753537 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,700

Underlying: Common Stock · 18,700 shares

Expires 2034-06-19

F1 · derivative.exercise_date: The option vests in full on the earlier of June 20, 2025 and the date of the 2025 Annual Meeting of Stockholders.

SEC source: 0000905148-24-001765 · form4.xml · derivative · entry 1

Feigal Ellen · CIK 0001758108 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,700

Underlying: Common Stock · 18,700 shares

Expires 2034-06-19

F1 · derivative.exercise_date: The option vests in full on the earlier of June 20, 2025 and the date of the 2025 Annual Meeting of Stockholders.

SEC source: 0000905148-24-001052 · form4.xml · derivative · entry 1

Mayer Timothy · CIK 0001775460 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,900

Underlying: Common Stock · 93,900 shares

Expires 2034-03-28

F1 · derivative.exercise_date: The option vests in full on the one year anniversary of the grant, March 29, 2025.

SEC source: 0000905148-24-001054 · form4.xml · derivative · entry 1

Richman Michael · CIK 0001366265 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 244,400

Underlying: Common Stock · 244,400 shares

Expires 2034-03-28

F1 · derivative.exercise_date: The option vests in full on the one year anniversary of the grant, March 29, 2025.

SEC source: 0000905148-24-001055 · form4.xml · derivative · entry 1

Shaw Kevin G. · CIK 0001953666 · Sr VP, General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,900

Underlying: Common Stock · 93,900 shares

Expires 2034-03-28

F1 · derivative.exercise_date: The option vests in full on the one year anniversary of the grant, March 29, 2025.

SEC source: 0000905148-24-001053 · form4.xml · derivative · entry 1

Myint Han · CIK 0001840942 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,900

Underlying: Common Stock · 93,900 shares

Expires 2034-03-28

F1 · derivative.exercise_date: The option vests in full on the one year anniversary of the grant, March 29, 2025.

SEC source: 0000905148-24-001051 · form4.xml · derivative · entry 1

Langermann Sol · CIK 0001775459 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,900

Underlying: Common Stock · 93,900 shares

Expires 2034-03-28

F1 · derivative.exercise_date: The option vests in full on the one year anniversary of the grant, March 29, 2025.

SEC source: 0000905148-24-001050 · form4.xml · derivative · entry 1

Kundu Sourav · CIK 0001872985 · Sr VP, Dev. & Mfg.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,900

Underlying: Common Stock · 52,900 shares

Expires 2034-03-28

F1 · derivative.exercise_date: The option vests in full on the one year anniversary of the grant, March 29, 2025.